MedTrace Logo

Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium

NCT04189666 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2020-07-09

No results posted yet for this study

Summary

180 patients will be randomly divided into two groups 90 patients each using a computer-generated program.

Group R: 90 patients will receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative Group M: 90 patients will receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative Patients in the two groups will be compared regarding incidence and severity of delirium on postoperative days 1, 2 or 3 and 7

Conditions

  • Delirium

Interventions

DRUG

Rivastigmine Transdermal System [Exelon]

compare the ability of the drug in preventing postoperative delirium

DRUG

Melatonin

compare the ability of the drug in preventing postoperative delirium

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Rania Hussien, MD · lLecturer of Anaesthesia, Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2020-04-10
Completion
2020-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04189666 on ClinicalTrials.gov